Intensive insulin therapy for type 2 diabetes at diagnosis

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 1, 2013, Pages 3-4

  DeVries, J Hans ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; INSULIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ASIA; CHINA; ETHNIC GROUP; HUMAN; INSULIN RESISTANCE; LETTER; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE; DIABETES MELLITUS, TYPE 2;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84882696770     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70001-9     Document Type: Letter

References (4)

1. Kramer CK, Zinman B, Retnakaran R Short-term intensive insulin therapy and its impact on type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013, published online Jan 30. http://dx.doi.org/10.1016/S0898-5898(13)00002-8.
2. DeVries JH, Snoek FJ, Kostense PJ, Heine RJ Improved glycaemic control in type 1 diabetes patients following participation per se in a clinical trial-mechanisms and implications. Diabetes Metab Res Rev 2003, 19:357-362.
3. Gale EA, Beattie SD, Hu J, Koivisto V, Tan MH Recruitment to a clinical trial improves glycemic control in patients with diabetes. Diabetes Care 2007, 30:2989-2992.
4. Pan Z, Trikalinos TA, Kavvoura FK, Lau J, Ioannidis JP Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature. PLoS Med 2005, 2:e334.